je.st
news
Tag: phase
VCO: CRO1878A-LF Features Remarkable Low Phase Noise Performance In The L-Band
2014-09-23 11:22:50| rfglobalnet News Articles
Z-Communications, Inc. announces a new RoHS compliant VCO (Voltage Controlled Oscillator) model CRO1878A-LF. The ceramic resonator based CRO1878A-LF operates at 1878 to 1879 MHz with a tuning voltage range of 1 to 4 Vdc.
Tags: low
features
performance
phase
Harris Corporation Installs First Phase Of High-Speed Weather Product Generation System For GOES-R Series Satellites
2014-09-23 11:17:54| rfglobalnet News Articles
Harris Corporation has installed and integrated the initial weather product applications onto the previously delivered ground segment hardware for the National Oceanic and Atmospheric Administration's (NOAA) Geostationary Operational Environmental Satellite — R (GOES-R) Series program.
Tags: system
product
series
corporation
MQ-4C Triton UAS Arrives At Naval Air Station Patuxent River, Enters Next Phase Of Testing
2014-09-19 08:28:58| rfglobalnet Home Page
The first U.S. Navy MQ-4C Triton unmanned aircraft system (UAS) has completed a flight from California to Maryland.
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
2014-09-17 15:31:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Moberg Pharma announces successful results for MOB-015 in a Phase II...
2014-09-17 10:42:21| Appliances - Topix.net
Moberg Pharma AB announces successful top-line results from a phase II study for MOB-015 in onychomycosis . The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.
Tags: results
ii
successful
phase
Sites : [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] next »